



Shanksville



New York City



Pentagon

State of the World Trade Center Health Program

CDR Brittany Rizek, MPH
Deputy Director, Management & Business

Enrollment Growth

Enrollment Category	Legacy Members	New Enrollees*	Total Enrollment	% Growth since 7/1/2011
Total	60,842	61,466	122,308	101.03%
General Responders	39,311	28,563	67,874	72.66%
FDNY Responders	16,806	244	17,050	1.45%
Survivors	4,725	32,659	37,384	691.20%

All data as of December 31, 2022, unless otherwise specified


Nationwide Provider Network Growth

This is a subset of the numbers above and includes 1,102 Pentagon responders and 129 Shanksville responders.


Enrollment Category	Legacy Members	New Enrollees*	Total Enrollment	% Growth since 7/1/2011
Total	7,677	21,994	29,671	286.49%
General Responders	7,092	8,489	15,581	
FDNY Responders	373	48	421	
Survivors	212	13,457	13,669	

Monthly Enrollment 1/01/2022–12/31/2022

Responders



Survivors



CCE/NPN Transfers From and To

Jan 22 – Dec 22	NYU	LIJMC	SUNY	MSSM	UMDNJ	FDNY	H+H	WSC	NPN
Transfers From	60	131	147	348	55	19	273	140	158
Transfers To	23	42	190	157	59	10	59	26	765
Total Activity	83	173	337	505	114	29	332	166	923

Members with Certifications by Categories of Conditions as of 12/31/2022

Category	Responders	Survivors	Combined
Aerodigestive Disorders	40,545	13,321	53,866
Cancers	17,694	13,460	31,154
Mental Health Conditions	14,699	6,952	21,651
Musculoskeletal Disorders and Acute Traumatic Injury	584	44	628
Total Number of Certified Members*	50,683	24,148	74,831

The figures are based on the number of members certified for each Zadroga Act condition category. Given that there are sometimes multiple certifications for one member within the same Zadroga Act condition category, the slide counts the member only once.

*The Total Number of Certified Members figures represent the specific number of members certified. Given that a member can be certified for multiple condition categories, the row counts the member only once. It is not a tally of the chart above the row.

Members with Certifications by Categories of Conditions as of 12/31/2022

Condition	Responders	Survivors	Combined
Chronic Rhinosinusitis	29,099	7,355	36,454
Gastroesophageal Reflux Disease (GERD)	27,054	6,218	33,272
All Cancers	17,694	13,460	31,154
Asthma	14,072	5,792	19,864
Sleep Apnea	16,059	1,735	17,794
Post-Traumatic Stress Disorder (PTSD)	9,690	4,248	13,938
Chronic Respiratory Disorder - Fumes / Vapors	8,000	1,312	9,312
WTC-Exacerbated/New Onset Chronic Obstructive Pulmonary Disease (COPD)	3,482	1,112	4,594
Anxiety Disorder (not otherwise specified)	2,691	1,143	3,834
Major Depressive Disorder	2,660	971	3,631
Depression (not otherwise specified)	2,359	529	2,888
Adjustment Disorder	1,482	982	2,464
Interstitial Lung Disease	1,312	635	1,947
Chronic Laryngitis	1,654	67	1,721
Substance Abuse	1,320	306	1,626
Generalized Anxiety Disorder	1,124	335	1,459
Chronic Nasopharyngitis	754	98	852
Panic Disorder	512	146	658
Dysthymic Disorder	295	325	620
Other Musculoskeletal Disorder and Acute Traumatic Injury	553	44	597
Upper Airway Hyperreactivity	420	99	519
Carpal Tunnel Syndrome	52	N/A	52
Low Back Pain	21	<10	22-30

Top 10 Certified Cancers - Responder Count by Year

Condition Category	2012-2017	2018	2019	2020	2021	2022	Total
Non-melanoma Skin	2,291	822	891	787	984	900	6,675
Prostate	1,501	496	544	523	559	527	4,150
Lymphoma	364	80	104	83	86	77	794
Melanoma of Skin	376	73	66	61	74	73	723
Kidney	284	93	75	89	85	76	702
Thyroid	320	93	71	85	78	53	700
Lung/Bronchus	275	67	76	70	86	79	653
Leukemia	240	73	61	62	62	57	555
Bladder	241	49	47	74	68	64	543
Colon	242	53	65	61	43	57	521
Total	6,134	1,899	2,000	1,895	2,125	1,963	16,016

Top 10 Certified Cancers - Survivor Count by Year

Condition Category	2012-2017	2018	2019	2020	2021	2022	Total
Prostate	237	238	633	542	591	678	2,919
Breast - Female	248	210	529	368	413	377	2,145
Non-melanoma Skin	143	108	415	324	458	593	2,041
Thyroid	136	100	210	154	151	142	893
Lymphoma	127	76	234	159	143	152	891
Lung/Bronchus	123	80	179	142	123	129	776
Kidney	76	49	132	97	88	113	555
Leukemia	84	56	122	82	81	83	508
Colon	48	45	106	82	121	85	487
Bladder	45	32	68	73	80	86	384
Total	1,267	994	2,628	2,023	2,249	2,438	11,599

As of December 31, 2022

The figures are based on the number of survivors certified for a specific cancer condition. A member can be counted in multiple Condition Categories.

Cancer Certifications - Decision Outcomes

	WTC-Related Conditions	Medically Associated Conditions	Total Conditions
Approvals	39,822	4,011	43,833
Redos	184	42	226
Denials	194	21	215
Admin Closure	4,400	798	5,198
Invalid	261	93	354
<i>Total Decisions Processed</i>	44,861	4,965	49,826
Conditions Under Review	91	16	107
<i>Total Conditions Processed</i>	44,952	4,981	49,933

Certified Rare Cancers - Responders

Type of Cancer	No. of Instances
Pancreas	188
Neuroendocrine	173
Testis	137
Brain	134
Connective Tissue	61
Breast - Male	36
Gallbladder/Biliary Tract	35
Nervous System	24
Thymus	21
Adrenal	<10
Bone	<10
Genital Organs	<10
Penis	<10
Small Intestine	<10
Uterine	<10

Certified Rare Cancers - Survivors

Type of Cancer	No. of Instances
Neuroendocrine	139
Pancreas	121
Testis	91
Brain	80
Breast - Male	47
Gallbladder/Biliary Tract	34
Thymus	22
Small intestine	20
Connective Tissue	12
Adrenal	<10
Bone	<10
Genital Organs	<10
Nervous System	<10
Penis	<10
Uterine	<10

As of December 31, 2022

The figures are based on the number of survivors certified for a specific cancer condition. A member can be counted in multiple Condition Categories.

Top 15 Drugs, July 2022–December 2022

Top 15 Drugs by Program Cost	
FY 23 Q1	FY 22 Q4
Drug	Drug
REVLIMID 10 MG CAPSULE	REVLIMID 10 MG CAPSULE
SYMBICORT 160-4.5 MCG INHALER	REVLIMID 5 MG CAPSULE
DUPIXENT 300 MG/2 ML PEN	SYMBICORT 160-4.5 MCG INHALER
SPRYCEL 100 MG TABLET	SPIRIVA HANDIHALER 18 MCG CAP
ABIRATERONE ACETATE 250 MG TAB	DUPIXENT 300 MG/2 ML PEN
SPIRIVA HANDIHALER 18 MCG CAP	POMALYST 4 MG CAPSULE
VENCLEXTA 100 MG TABLET	SPRYCEL 100 MG TABLET
OFEV 150 MG CAPSULE	ABIRATERONE ACETATE 250 MG TAB
REVLIMID 5 MG CAPSULE	VENCLEXTA 100 MG TABLET
TRELEGY ELLIPTA 100-62.5-25	TRELEGY ELLIPTA 100-62.5-25
IMBRUVICA 420 MG TABLET	OFEV 150 MG CAPSULE
POMALYST 4 MG CAPSULE	SPIRIVA RESPIMAT 2.5 MCG INH
SPIRIVA RESPIMAT 2.5 MCG INH	BUDESONIDE-FORMOTEROL 160-4.5
TRELEGY ELLIPTA 200-62.5-25	ALBUTEROL HFA 90 MCG INHALER
BUDESONIDE-FORMOTEROL 160-4.5	TRELEGY ELLIPTA 200-62.5-25

Top 15 Drugs by Claim Volume			
FY 23 Q1		FY 22 Q4	
Drug	Volume	Drug	Volume
ALBUTEROL HFA 90 MCG INHALER	6,545	ALBUTEROL HFA 90 MCG INHALER	6,394
FLUTICASONE PROP 50 MCG SPRAY	6,386	FLUTICASONE PROP 50 MCG SPRAY	5,994
MONTELUKAST SOD 10 MG TABLET	4,189	MONTELUKAST SOD 10 MG TABLET	4,127
OMEPRAZOLE DR 40 MG CAPSULE	3,801	OMEPRAZOLE DR 40 MG CAPSULE	3,449
FAMOTIDINE 40 MG TABLET	2,869	FAMOTIDINE 40 MG TABLET	2,651
PANTOPRAZOLE SOD DR 40 MG TAB	2,833	PANTOPRAZOLE SOD DR 40 MG TAB	2,535
FAMOTIDINE 20 MG TABLET	2,052	FAMOTIDINE 20 MG TABLET	1,920
NEILMED SINUS RINSE KIT	1,980	NEILMED SINUS RINSE KIT	1,781
OMEPRAZOLE DR 20 MG CAPSULE	1,904	OMEPRAZOLE DR 20 MG CAPSULE	1,769
LEVOCETIRIZINE 5 MG TABLET	1,861	LEVOCETIRIZINE 5 MG TABLET	1,756
AZELASTINE 0.1% (137 MCG) SPRY	1,847	AZELASTINE 0.1% (137 MCG) SPRY	1,661
VENTOLIN HFA 90 MCG INHALER	1,822	CETIRIZINE HCL 10 MG TABLET	1,640
CETIRIZINE HCL 10 MG TABLET	1,687	VENTOLIN HFA 90 MCG INHALER	1,554
ESOMEPRAZOLE MAG DR 40 MG CAP	1,508	ESOMEPRAZOLE MAG DR 40 MG CAP	1,447
AZELASTIN-FLUTIC 137-50MCG SPR	1,175	NEILMED SINUS RINSE KIT REFILL	1,140

Service Delivery Contracts

- Recent Vendor Transitions
 - Nationwide Provider Network (NPN): Managed Care Advisors (MCA)-Sedgwick (started August 2022)
 - Pharmacy Benefit Manager (PBM): Express Scripts Inc. (started June 2022)
- Third Party Administrator (TPA) to replace the Health Program Support (HPS)
 - TPA award is under protest
- Clinical Centers of Excellence (CCEs) awarded (October 2022)

Responder CCEs		Survivor CCEs
FDNY	Northwell Health	NYC Health + Hospitals
Mount Sinai	Rutgers	William Street Clinic (Optum Serve)
New York University	SUNY Stony Brook	

Implementation of New Vendor to Administer the Nationwide Provider Network (as of January 26, 2023)

- Managed Care Advisors started health care delivery August 1, 2022
- Successfully provided warm transfers (LHI>MCA) to ~100 high acuity members
- 36,698 Calls answered at NPN call center
- Member and provider portal available to NPN members
- 908 total members in case management; 318 in intensive case management
- 559 annual monitoring exams and 594 initial health evaluations completed
- 1,073 members certified since go live; 1,542 conditions certified
- LHI/OptumServe will process runout claims with DOS prior to 8/1/2022 through early 2024

NPN Transition Challenges

- Call Center / Chat Function
 - Long wait times early in transition
 - Significant improvement since early months of transition
- Out of Network (OON) Providers
 - Identification of network gaps (geographically and specialty)
 - Recruitment of providers to address gaps
 - OON Provider services being authorized as required to ensure continuity of care

Implementation of New Pharmacy Benefit Manager Vendor

- On June 1st, 2022, the Program switched Pharmacy Benefits Managers from Optum to Express Scripts
- Key Accomplishments:
 - Transferred 118,456 members data from Optum to Express Scripts
 - Transferred over 13,000 members from OptumRx Home Delivery to Express Scripts Home Delivery
 - Filled 380,000 prescriptions from June 1st to December 31st, 2022
 - Transitioned 164 qualifying members to Express Scripts Accredo Specialty Pharmacy
 - 90-day supply prescriptions have increased by 8% of total which improves medication adherence
 - Increased coordination of benefits for survivors by 55%
 - Implemented new:
 - Pharmacy networks for responders and survivors
 - Prior authorization process and systems
 - Pharmacy Benefits Manager call center and communications (letters)
 - Member portal

Implementation of New Pharmacy Benefit Manager Vendor

- Challenges:
 - Setting up PBM systems to adhere to WTC Health Program unique requirements
 - Training PBM staff on the Program
 - Training CCE/NPN staff on new PBM systems and processes
 - Member and call center communications
 - Implementing new coordination of benefits system for survivors
 - Medicaid primary payer issue
 - Data transfer problems

Looking to the future

- By 2030, most of Program membership will be >65 years old.
- Intersection between debilitating WTC-related conditions and age-related diseases, disorders, and disabilities.
- Aging still the primary risk factor for hearing loss, osteoarthritis, back/neck pain, Type 2 diabetes, refractive visual impairments, urinary incontinence, heart disease, cancers, cognitive decline and falls.
- Expect aging to impact the quality of life of our members.
- Challenge – provide resources to members to maintain a high quality of life.
- Find innovative ways to recruit behavioral/mental health and end of life and home health providers nationally.